B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity

References

• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008; 2008: 450–456
   Google Scholar
• Hamblin T J, Oscier D G, Young B J. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986; 39: 713–716
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815
   PubMed Web of Science ®Google Scholar
• Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188: 1185–1190
   PubMed Web of Science ®Google Scholar
• Ohata J, Zvaifler N J, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174: 864–870
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning J L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465–475
   PubMed Web of Science ®Google Scholar
• Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 2003; 14: 311–324
   PubMed Web of Science ®Google Scholar
• Tangye S G, Bryant V L, Cuss A K, Good K L. BAFF, APRIL and human B cell disorders. Semin Immunol 2006; 18: 305–317
   PubMed Web of Science ®Google Scholar
• Mackay F, Silveira P A, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007; 19: 327–336
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Davidson A. The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther 2004; 6: 197–202
   PubMed Web of Science ®Google Scholar
• Ansell S M, Witzig T E, Inwards D J, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008; 14: 1105–1110
   PubMed Web of Science ®Google Scholar
• Kofler D M, Elter T, Gianella-Borradori A, et al. A phase Ib trial of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed B-cell chronic lymphocytic leukemia (B-CLL) [abstract]. J Clin Oncol 2007; 25: 18S, Abstract 3029
   Google Scholar
• Ponce R, Miller D. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol Pathol 2009; 37: 89–99
   PubMed Web of Science ®Google Scholar
• Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747–1756
   PubMed Web of Science ®Google Scholar
• Dillon S R, Gross J A, Ansell S M, Novak A J. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235–246
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu L, Opalka N, Kappler J, Shu H B, Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002; 108: 383–394
   PubMed Web of Science ®Google Scholar
• Oren D A, Li Y, Volovik Y, et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 2002; 9: 288–292
   PubMedGoogle Scholar
• Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201: 195–200
   PubMed Web of Science ®Google Scholar
• Morimoto S, Nakano S, Watanabe T, et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007; 46: 1083–1086
   PubMed Web of Science ®Google Scholar
• Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198–204
   PubMed Web of Science ®Google Scholar
• Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297–302
   PubMed Web of Science ®Google Scholar
• Craxton A, Magaletti D, Ryan E J, Clark E A. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003; 101: 4464–4471
   PubMed Web of Science ®Google Scholar
• Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb J P. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006; 118: 281–292
   PubMed Web of Science ®Google Scholar
• Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006; 18: 263–275
   PubMed Web of Science ®Google Scholar
• Bodmer J L, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27: 19–26
   PubMed Web of Science ®Google Scholar
• Kim H M, Yu K S, Lee M E, et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat Struct Biol 2003; 10: 342–348
   PubMedGoogle Scholar
• von Bulow G U, Bram R J. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278: 138–141
   PubMed Web of Science ®Google Scholar
• Wu Y, Bressette D, Carrell J A, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000; 275: 35478–35485
   PubMed Web of Science ®Google Scholar
• Reyes S L, Leon B F, Rozas V M, Gonzalez J P, Naves P R. BAFF: a regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer. Rev Med Chil 2006; 134: 1175–1184
   PubMed Web of Science ®Google Scholar
• Laabi Y, Gras M P, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J 1992; 11: 3897–3904
   PubMed Web of Science ®Google Scholar
• O'Connor B P, Raman V S, Erickson L D, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91–98
   PubMed Web of Science ®Google Scholar
• Darce J R, Arendt B K, Wu X, Jelinek D F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007; 179: 7276–7286
   PubMed Web of Science ®Google Scholar
• Salzer U, Jennings S, Grimbacher B. To switch or not to switch – the opposing roles of TACI in terminal B cell differentiation. Eur J Immunol 2007; 37: 17–20
   PubMed Web of Science ®Google Scholar
• Xia X Z, Treanor J, Senaldi G, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000; 192: 137–143
   PubMed Web of Science ®Google Scholar
• Xu S, Lam K P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001; 21: 4067–4074
   PubMed Web of Science ®Google Scholar
• Yan M, Wang H, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001; 2: 638–643
   PubMed Web of Science ®Google Scholar
• Fagarasan S, Honjo T. T-Independent immune response: new aspects of B cell biology. Science 2000; 290: 89–92
   PubMed Web of Science ®Google Scholar
• Castigli E, Wilson S A, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005; 201: 35–39
   PubMed Web of Science ®Google Scholar
• Castigli E, Wilson S A, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37: 829–834
   PubMed Web of Science ®Google Scholar
• Darce J R, Arendt B K, Wu X, Jelinek D F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007; 179: 7276–7286
   PubMed Web of Science ®Google Scholar
• Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280–288
   PubMed Web of Science ®Google Scholar
• Aggarwal B B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745–756
   PubMed Web of Science ®Google Scholar
• He J Q, Zarnegar B, Oganesyan G, et al. Rescue of TRAF3-null mice by p100 NF-κB deficiency. J Exp Med 2006; 203: 2413–2418
   PubMed Web of Science ®Google Scholar
• Xu Y, Cheng G, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996; 5: 407–415
   PubMed Web of Science ®Google Scholar
• Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005; 102: 2874–2879
   PubMed Web of Science ®Google Scholar
• Thien M, Phan T G, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785–798
   PubMed Web of Science ®Google Scholar
• Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007; 136: 309–314
   PubMed Web of Science ®Google Scholar
• Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3: 424–429
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Masumoto K, et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42: 980–985
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1065–1067
   PubMed Web of Science ®Google Scholar
• Lee Y H, Ota F, Kim-Howard X, Kaufman K M, Nath S K. APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility. Rheumatology (Oxford) 2007; 46: 1274–1276
   PubMed Web of Science ®Google Scholar
• Tan S M, Xu D, Roschke V, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982–992
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled S L, Cutler A H, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59–68
   PubMed Web of Science ®Google Scholar
• Hever A, Roth R B, Hevezi P, et al. Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator. Proc Natl Acad Sci USA 2007; 104: 12451–12456
   PubMed Web of Science ®Google Scholar
• Kim J Y, Yang Y, Moon J S, et al. Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 2008; 199: 151–154
   PubMed Web of Science ®Google Scholar
• Mackay I R, Groom J, Mackay C R. Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 2002; 35: 551–553
   PubMed Web of Science ®Google Scholar
• Cohen S B. Updates from B Cell trials: efficacy. J Rheumatol Suppl 2006; 77: 12–17
   PubMedGoogle Scholar
• Kern C, Cornuel J F, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103: 679–688
   PubMed Web of Science ®Google Scholar
• Kim S J, Lee S J, Choi I Y, et al. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol 2008; 81: 177–184
   PubMed Web of Science ®Google Scholar
• Schwaller J, Went P, Matthes T, et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 2007; 21: 1324–1327
   PubMed Web of Science ®Google Scholar
• Schwaller J, Schneider P, Mhawech-Fauceglia P, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007; 109: 331–338
   PubMed Web of Science ®Google Scholar
• Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007; 109: 729–739
   PubMed Web of Science ®Google Scholar
• Ng L G, Sutherland A P, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173: 807
   PubMed Web of Science ®Google Scholar
• Briones J, Timmerman J M, Hilbert D M, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002; 30: 135–141
   PubMed Web of Science ®Google Scholar
• He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172: 3268–3279
   PubMed Web of Science ®Google Scholar
• Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148–3157
   PubMed Web of Science ®Google Scholar
• Novak A J, Grote D M, Ziesmer S C, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006; 24: 983–987
   PubMed Web of Science ®Google Scholar
• Herreros B, Sanchez-Aguilera A, Piris M A. Lymphoma microenvironment: culprit or innocent?. Leukemia 2008; 22: 49–58
   PubMed Web of Science ®Google Scholar
• Novak A J, Grote D M, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104: 2247–2253
   PubMed Web of Science ®Google Scholar
• He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003; 171: 5215–5224
   PubMed Web of Science ®Google Scholar
• Molica S, Digiesi G, Mauro F, et al. Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res 2009; 33: 162–165
   PubMed Web of Science ®Google Scholar
• Planelles L, Castillo-Gutierrez S, Medema J P, et al. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 2007; 92: 1284–1285
   PubMed Web of Science ®Google Scholar
• Novak A J, Bram R J, Kay N E, Jelinek D F. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100: 2973–2979
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 380–388
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood 2005; 106: 1012–1020
   PubMed Web of Science ®Google Scholar
• Burger J A, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655–2663
   PubMed Web of Science ®Google Scholar
• Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway. Blood 2007; 109: 703–710
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052–1057
   PubMed Web of Science ®Google Scholar
• Smit L A, Hallaert D Y, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007; 109: 1660–1668
   PubMed Web of Science ®Google Scholar
• Mittal A K, Iqbal J, Nordgren T M, et al. Molecular basis of proliferation/survival and migration of CLL in peripheral blood, bone marrow and lymph nodes [abstract]. Blood 2008, 112. Abstract 546
   PubMed Web of Science ®Google Scholar
• Enzler T, Widhopf G F, Lee J, et al. BAFF Accelerates development of chronic lymphocytic leukemia in TCL1 transgenic mice [abstract]. Blood 2007, 110. Abstract 1117
   Web of Science ®Google Scholar
• Enzler T, Zhang W, Kater A P, et al. Constitutive Baff signalling plays a key role in CLL development by promoting tumor cell survival [abstract]. Blood 2008, 112. Abstract 28
   Web of Science ®Google Scholar
• Planelles L, Carvalho-Pinto C E, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004; 6: 399–408
   PubMed Web of Science ®Google Scholar
• Vanura K, Le T, Esterbauer H, et al. Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica 2008; 93: 1912–1916
   PubMed Web of Science ®Google Scholar
• Ekstrom S K, Vajdic C M, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111: 4029–4038
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Lyu M A, Du M, et al. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 2007; 109: 2557–2564
   PubMed Web of Science ®Google Scholar